NewsNew Study Data Shows Diabetic Foot Ulcers Treated with Granulox Demonstrated Significantly Better and More Rapid Wound Closure

New Study Data Shows Diabetic Foot Ulcers Treated with Granulox Demonstrated Significantly Better and More Rapid Wound Closure

Diabetic foot ulcers, Products

New Study Data Shows Diabetic Foot Ulcers Treated with Granulox Demonstrated Significantly Better and More Rapid Wound ClosureA new study has found – Innovative oxygen therapy, Granulox®, to be an effective, safe and easy-to-use treatment, with the potential to revolutionise wound care, according to a new study published in the recent edition of Diabetic Foot and Ankle Journal. The comprehensive study – the first of its kind in the UK – was conducted by South Tees NHS Hospitals Foundation Trust and treated 40 patients with non-healing diabetic foot ulcers that were present for 12 weeks or more, with Granulox® haemoglobin spray. After just four weeks, all trial patients reported a reduction in wound surface area, elimination of slough and an improvement in exudate levels.

  • Wound size: At week 4 of the study, patients using Granulox® saw a rapid reduction in overall wound size with an average of 63% reduction area compared to just 26% in the control group.  This reached 95% reduction in wound area by the end of the trial at week 28 compared to just 63% in the control group.
  • Pain: Both the trial and control patient groups started from a mean pain score of 5.1.  The patients treated with Granulox® were all completely pain free by week 12 compared to the control group where 6 patients were still suffering with a mean pain score of 3.7.
  • Slough/exudate: With the use of Granulox®, complete slough elimination was achieved after just 4 weeks compared to only a 10% reduction in the control group.  In addition after just 4 weeks of using the treatment 100% of patients demonstrated a significant reduction in exudate compared to just 44% in the control group.  These results demonstrate the transformative impact of Granulox® in patients with previously non-healing wounds.

 Both the patient and clinician experience of Granulox® was positive, with the treatment’s easy-to-use spray functionality hailed as a key product benefit.